AVPT vs CALX

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth (23.6% YoY) and strong gross margins (74.51%), profitability remains thin with only a 0.50% net margin and weak ROE (0.67%). Analysts recommend a 'buy' with a $19.02 target, implying 51% upside, but insider selling of $89.11M over the last six months contradicts this optimism. The stock trades at a high forward P/E of 32.18, above sector averages, while recent price performance is bearish (-31.3% over 1Y), reflecting market skepticism despite improving earnings trends.

CALX exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a negligible Debt/Equity ratio of 0.02, indicating a very stable balance sheet. However, there is a severe disconnect between the current price ($43.38) and deterministic value metrics, with the Graham Number at $11.88 and Intrinsic Value at $3.43. While the Forward P/E of 17.33 suggests significant earnings growth potential, the stock is currently plagued by heavy insider selling ($54.23M) and a sharp bearish technical trend. The overall outlook is neutral as the high-quality financial health is offset by extreme valuation premiums and negative sentiment.